


## CTP Synthetase-IN-1

<b>Cat. No.:</b>	HY-152149		
<b>CAS No.:</b>	2338811-71-3		
<b>Molecular Formula:</b>	C <sub>20</sub> H <sub>19</sub> F <sub>3</sub> N <sub>6</sub> O <sub>3</sub> S <sub>2</sub>		
<b>Molecular Weight:</b>	512.53		
<b>Target:</b>	DNA/RNA Synthesis		
<b>Pathway:</b>	Cell Cycle/DNA Damage		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (195.11 mM; Need ultrasonic)

Solvent	Mass	Concentration		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.9511 mL	9.7555 mL	19.5111 mL
	5 mM	0.3902 mL	1.9511 mL	3.9022 mL
	10 mM	0.1951 mL	0.9756 mL	1.9511 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

CTP Synthetase-IN-1 is a potent, orally active cytidine 5'-triphosphate synthetase (CTPS) inhibitor with IC<sub>50</sub>s of 32 nM and 18 nM for human CTPS1 and human CTPS2, respectively. CTP Synthetase-IN-1 has anti-inflammatory effects<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

IC<sub>50</sub>: 32 nM (human CTPS1) and 18 nM (human CTPS2)<sup>[1]</sup>

#### In Vitro

CTP Synthetase-IN-1 (compound 27) inhibits rat CTPS1, rat CTPS2, mouse CTPS1, and mouse CTPS2 with IC<sub>50</sub> values of 27 nM, 23 nM, 26 nM, and 33 nM, respectively<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### In Vivo

CTP Synthetase-IN-1 (compound 27; 10-50 mg/kg; p.o; twice daily; for 18 days) shows significant pharmacological responses in collagen-induced arthritis (CIA) model<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mouse collagen-induced arthritis (CIA) model <sup>[1]</sup>
---------------	---

Dosage:	10 mg/kg and 50 mg/kg
Administration:	p.o; twice daily; for 18 days
Result:	Resulted in improvements in specific indicators of disease severity.

## REFERENCES

[1]. Andrew Novak, et al. Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation. J Med Chem. 2022 Dec 22;65(24):16640-16650.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA